Decode Age raises Rs 14.48 Cr to advance longevity science and gut microbiome research

Decode Age, a longevity science organisation focused on ageing biology, biomarker research and gut microbiome science, has raised Rs 14.48 crore in its Pre Series A funding round led by Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India Limited. 

With over forty years of experience in the pharmaceutical industry, Dr Prasad has been a pioneer of innovation, scale and manufacturing excellence. 

The investment strengthens the company’s mission to make the biology of ageing measurable, understandable and actionable through science led solutions and a microbiome centred longevity ecosystem.

Decode Age has built a comprehensive longevity research platform that spans multi omics testing, biomarker discovery and precision-based interventions. At the heart of this ecosystem is one of India’s most advanced whole genome gut microbiome analysis systems, providing high resolution insights into microbial diversity and its influence on immunity, metabolism and ageing pathways. Its laboratory workflows prioritise precision and reproducibility, supporting researchers, clinicians and individuals who seek deeper biological understanding and practical tools for healthy ageing.

The new capital will enable Decode Age to expand biomarker discovery programmes, advance its multi omics and microbiome research pipeline and enhance scientific and analytical infrastructure. It will also support formulation research aligned with key hallmarks of ageing, including areas such as cellular energy, metabolic balance, inflammatory pathways and cognitive resilience, as well as deeper collaboration across the longevity ecosystem. 

Decode Age is now also building a world class scientific, clinical, and product team to take India’s longevity innovation to a global audience. The company aims to position India as a leader in microbiome science and healthy ageing research, and to create solutions that meet international standards of scientific rigour, quality and translational value. This next phase of growth will strengthen its ability to operate at global research scale while delivering accessible, evidence backed longevity solutions for consumers.